Pharmaceutical composition and application thereof

A drug and composition technology, applied in the field of drug combination and its application, can solve the problem of single species, achieve the effect of lowering blood sugar, reducing abnormal remodeling and fibrosis, and promoting the outcome of inflammation

Pending Publication Date: 2022-03-15
BEIJING WEIFENG YIMIN TECH
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The technical problem to be solved by the present invention is to overcome the single defect of existin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition and application thereof
  • Pharmaceutical composition and application thereof
  • Pharmaceutical composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1: Establishment of animal model of diabetic nephropathy, grouping of animals, screening of berberine hydrochloride and stachyose compatibility

[0042] SPF grade ICR mice (male, 3-4 weeks old) were bred in the GLP Experimental Animal Center, with constant temperature and humidity, free to eat and drink. After one week of adaptive feeding, the mice were randomly divided into two groups according to sex and body weight: ① 10 mice in the normal control group were given basal feed until the end of the experiment; ② 140 mice in the high-fat+STZ group were given high-fat and high-sugar feed (containing 35% fat, 18% protein, 47% carbohydrate), continued for 4 weeks after intraperitoneal injection of streptozotocin STZ 100mg / kg (dissolved in 0.1M citric acid buffer, pH4.5), and continued to give high fat and high sugar Feed (the mice in the normal group were injected intraperitoneally with solvent 0.1M citrate buffer). Blood glucose (BG) was detected by taking blood f...

Embodiment 2

[0053] Example 2: Effects of berberine hydrochloride and stachyose alone and in combination on renal function in mice with diabetic nephropathy

[0054] SPF grade ICR mice (male, 3-4 weeks old) were bred in the GLP Experimental Animal Center, with constant temperature and humidity, free to eat and drink. After one week of adaptive feeding, the mice were randomly divided into 2 groups according to body weight: (1) normal group (ie, control group) of 10 mice, which were given basal feed until the end of the experiment; (2) high-fat+STZ group of 40 mice.

[0055] The specific modeling scheme is: high fat+STZ group mice are given high fat high sugar diet (containing 35% fat, 18% protein, 47% carbohydrate), and after continuing for 4 weeks, intraperitoneal injection of streptozotocin STZ 100mg / kg ( Dissolved in 0.1M citric acid buffer, pH 4.5), and continued to give high-fat and high-sugar feed (the normal group mice were injected intraperitoneally with solvent 0.1M citric acid buf...

Embodiment 3

[0060] Example 3: Effects of berberine hydrochloride and stachyose alone and in combination on blood sugar, creatinine and blood urea nitrogen in mice with diabetic nephropathy

[0061] After 8 weeks of continuous administration, after the mice were fasted for 12 hours, blood was taken from the tail vein, and the fasting blood glucose was measured using a blood glucose detector. Blood glucose, according to the formula AUC(mmol / L / h)=(0min blood glucose level+30min blood glucose level)×0.5 / 2+(30min blood glucose level+60min blood glucose level)×0.5 / 2+(60min blood glucose level+120min blood glucose level) ×1 / 2 Calculate the area under the curve to evaluate the glucose tolerance of mice. After 24 hours of resumption of diet, 1 mL of blood was collected from the mice through the orbital vein, left at room temperature for 30 minutes, centrifuged at 3000 rpm for 10 minutes, the serum was separated, and the contents of serum creatinine and urea nitrogen were detected using a Hitachi 7...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition and application thereof. The invention provides an application of a medicine composition in preparation of a medicine for treating and/or preventing diabetic nephropathy. The medicine composition comprises berberine hydrochloride and stachyose. The invention also discloses a pharmaceutical composition for treating and/or preventing diabetic nephropathy. The pharmaceutical composition disclosed by the invention can be used for improving the renal function of a diabetic model mouse induced by high fat diet and STZ, specifically, the content of blood sugar, creatinine and urea nitrogen in blood and urine ACR are remarkably reduced, inflammation outcome in the kidney of the diabetic mouse is promoted, and abnormal reconstruction and fibrosis of kidney tissues are relieved. The invention provides a scientific basis for reasonable use of the combination of berberine hydrochloride and stachyose in the field of prevention and treatment of diabetic nephropathy.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a medicine combination and its application. Background technique [0002] The incidence rate of diabetes in China is 11.6%, accounting for about 27% of the global diabetic patients, and it is the largest country in diabetes. Among them, diabetic nephropathy (diabetic nephropathy, DN) is one of the common complications of diabetes, and 30%-40% of diabetic patients may develop diabetic nephropathy. It is characterized by progressive decline. As the disease worsens and the course of the disease prolongs, renal fibrosis gradually occurs, which can progress to end-stage renal disease. It is the main cause of disability and death in diabetic patients. The incidence of diabetic nephropathy in my country is also on the rise, and it has become the second cause of end-stage renal disease, second only to various glomerulonephritis. Due to its complex metabolic disorders, once...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4375A61K31/702A61P3/10A61P13/12
CPCA61K31/4375A61K31/702A61P3/10A61P13/12A61K2300/00
Inventor 胡卓伟
Owner BEIJING WEIFENG YIMIN TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap